Effectiveness of the Petö Method on Gross Motor Function in Children With Cerebral Palsy: a Quasi-experimental Pilot Study. (Petö method)

March 17, 2026 updated by: SAGRARIO PÉREZ DE LA CRUZ, Universidad de Almeria

EFFECTIVENESS OF THE PETÖ METHOD ON GROSS MOTOR FUNCTION IN CHILDREN WITH CEREBRAL PALSY: A QUASI-EXPERIMENTAL PILOT STUDY.

Cerebral palsy is the most frequent cause of physical disability in childhood. The Petö Method proposes a comprehensive pedagogical-therapeutic approach to improve functionality. Historically, the Petö Method (Conductive Education) has faced skepticism regarding its clinical efficacy. Notable reports, such as the one by the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM), have previously concluded that there was insufficient evidence to support its use. However, these critiques emphasized that prior studies suffered from serious methodological deficiencies and a lack of validated measurement instruments.

Our study directly addresses these gaps by implementing the Gross Motor Function Measure-66 (GMFM-66). Unlike older scales, the GMFM-66 provides a valid and reliable estimate of motor behavior in children with CP, offering the sensitivity required to detect minimal yet clinically relevant changes.

In our results, the Petö Method is shown to be an effective intervention for improving gross motor function in children with significant levels of motor impairment. The observed changes are not only statistically significant but also clinically relevant, exceeding the minimal detectable change and promoting functional autonomy in activities of daily living.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

13

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Almería, Spain, 04120
        • University of Almeria

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The sample consisted of thirteen pediatric patients diagnosed with cerebral palsy (CP). The inclusion criteria were age between 4 and 9 years (inclusive), diagnosis of spastic cerebral palsy, with motor impairment of level III and IV (Gross Motor Function Classification System - GMFCS), sufficient cognitive competence to understand and execute simple commands. In addition, participants were required to have completed a three-month therapeutic rest period without any other type of prior therapy (to ensure the 'novelty' effect of the therapy and avoid contamination with other interventions). Exclusion criteria included the presence of severe sensory deficits and serious behavioral disorders that could interfere with the group dynamics of the intervention. It should be noted that epilepsy under pharmacological control was not a reason for exclusion from this study.

The exclusion of a control group from this study was due to recruitment issues, as it was not possible to obtain a sample wit

Description

Inclusion Criteria:

  • Age between 4 and 9 years (inclusive)
  • Diagnosis of spastic cerebral palsy, with motor impairment of level III and IV (Gross Motor Function Classification System - GMFCS)
  • Sufficient cognitive competence to understand and execute simple commands. - - To have completed a three-month therapeutic rest period without any other type of prior therapy (to ensure the 'novelty' effect of the therapy and avoid contamination with other interventions).

Exclusion Criteria:

  • The presence of severe sensory deficits and serious behavioral disorders that could interfere with the group dynamics of the intervention.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
GMFM 66
Time Frame: Five months
Four areas were distinguished: manipulation, arm mobility, leg mobility, and postural control. The GMFM-66 scale has been designed and validated in a population of children with CP aged between 5 months and 16 years. Its purpose is to assess different dimensions of gross motor skills in children with CP and to record changes over time in the characteristics or attributes of gross motor behavior.
Five months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Bax, M., Goldstein, M., Rosenbaum, P., Leviton, A., Paneth, N., Dan, B. & Damiano, D. Proposed definition and classification of cerebral palsy. Dev. Med. Child Neurol. 47, 571-576 (2005).

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2018

Primary Completion (Actual)

March 1, 2019

Study Completion (Actual)

March 1, 2022

Study Registration Dates

First Submitted

March 13, 2026

First Submitted That Met QC Criteria

March 17, 2026

First Posted (Actual)

March 20, 2026

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Patient´s information is subject to the laws of the country

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Clinical Trials on Education

Subscribe